EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2025 Interim Results at a glance

2025.08.26

Resilient Interim Results: Essex Bio-Technology Drives Growth and Innovation, Revenue up 5.8% to HK$876.5 Million, Profit up 3.8% to HK$ 163.4 million, 16.7% Dividend Surge, Continued Innovation Momentum in Regulatory Milestones

2025.08.26

NMPA Accepted Essex’s Biologics License Application for EB12-20145P (HLX04-O) for the Treatment of Wet Age-Related Macular Degeneration.

2025.08.13

Date

Title

2022-05-07

Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC

2022-04-29

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting

2022-04-19

First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2022-04-08

First Patient Dosed in a Global Multi-Centre Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for treatment of Ophthalmic Diseases in the EU

2022-03-22

Essex Bio-Technology Announces 2021 Financial Results Achieves an increase of 58% in Profit-After-Tax to HK$346.0 million and Turnover Growth of 67.4% to HK$1,637.7 million

2021-12-20

Essex Bio-Technology Wins "Best Investment Value Award for Listed Companies" under China Securities Golden Bauhinia Awards Gains Wide Recognition from Capital Market for Comprehensive Strength and Investment Value

2021-11-10

First Patient First Visit Completed in the PRC in a Phase 3 Clinical Trial of Bevacizumab EB12-20145P (HLX04-O)

2021-10-27

Essex Bio-Technology to Present at the 5th China Bio-Pharm Partnering Forum (Bio-Pharm 2021)

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT